[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634288":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":26,"responsibleParty":47,"collaborators":10,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":10,"studyType":62,"phases":10,"briefSummary":63,"conditions":64,"keywords":67,"overallStatus":28,"whyStopped":10,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Peking University People's Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"AML patients with MLL rearrangement",null,"AML patients with MLL rearrangement who recieved chemnoptherapy or unerwent allo-SCT",[13],"Diagnostic Test: Detection of leukemia stem cell using multiparameter flow cytometry",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DIAGNOSTIC_TEST","Detection of leukemia stem cell using multiparameter flow cytometry","For AML patients with MLL rearrangement enrolled, leukemia stem cell will be detcted at diagnosis and during follow-up. A traditional Minimal residual disease was deteced as normal medical care, simultaneously, leukemia stem cell will be detcted using the sample bone marrow sample.",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Siqi Li, PhD","CONTACT","+86 18611944638","tina_li_1995@163.com",[27],{"facility":5,"status":28,"city":29,"state":10,"zip":10,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"RECRUITING","Beijing","China","CN",{"type":33,"coordinates":34},"Point",[35,36],116.39723,39.9075,{"lat":36,"lon":35},[39,40,44],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},{"name":41,"role":23,"phone":42,"phoneExt":10,"email":43},"YingJun Chang, PhD","010-86491529","pk200608@126.com",{"name":45,"role":46,"phone":10,"phoneExt":10,"email":10},"Siqi Li","PRINCIPAL_INVESTIGATOR",{"type":46,"investigatorFullName":45,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Chief Technician","100634288","leukemia-stem-cell-based-assay-to-predict-relapse-and-survival-in-patients-with-acute-myeloid-leukemia-100634288",false,"NCT07537738","Leukemia Stem Cell-based Assay to Predict Relapse and Survival in Patients With Acute Myeloid Leukemia","MLL-LSC","Inclusion Criteria:\n\nAcute myeloiud leukemia patients with MLL arrangement aging 6-60 years recieving chemoterapy or allo-geneic hematopoietic stem cell transplantation.\n\nExclusion Criteria:\n\n1. Patients who cannot recieve chemoterapy or allo-geneic hematopoietic stem cell transplantation.\n2. Patients who cannot comply with the study.","ALL","6 Years","60 Years",{"count":60,"type":61},210,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn about the predict value of leukemia stem cell for acute myeloid leukemia patients with MLL-rearrangement. The main question it aims to answer is:\n\n• Could be leukemia stem cell used for relapse prediction in acute myeloid leukemia patients with MLL-rearrangement? Leukemia stem cell will be detected at the same time for participants who detected minimal residual disease using bone marrow as part of their regular medical care to answer the question.",[65,66],"Acute Myeloid Leukemia (AML)","MLL Rearrangement",[68,69,70],"acute myeloid leukemia","leukemia stem cell","allo-SCT","2026-04-13",{"date":73,"type":74},"2026-04-17","ACTUAL",{"date":76,"type":74},"2025-06-01",{"date":78,"type":61},"2026-04-07",{"name":5,"class":6},1]